Patents by Inventor Mike Trower

Mike Trower has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL USES
    Publication number: 20240108621
    Abstract: This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses.
    Type: Application
    Filed: November 28, 2023
    Publication date: April 4, 2024
    Applicant: NeRRe Therapeutics Limited
    Inventors: Mike Trower, Stephen Pawsey, Mary Kerr
  • Uses
    Patent number: 11872222
    Abstract: This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: January 16, 2024
    Assignee: NeRRe Therapeutics Limited
    Inventors: Mike Trower, Stephen Pawsey, Mary Kerr
  • METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE
    Publication number: 20230382922
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: July 31, 2023
    Publication date: November 30, 2023
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike TROWER, Monica LAZARO, Derek BUSH, David ELDER, Mary KERR
  • Method of treating certain sex hormone-dependent diseases administering a soft gelatin capsule comprising NK1 and NK3 receptors antagonists
    Patent number: 11787820
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: October 17, 2023
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • Method of treatment of symptoms of menopause
    Patent number: 11767328
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: January 13, 2023
    Date of Patent: September 26, 2023
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • AN NK-1 RECEPTOR ANTAGONIST FOR TREATING A DISEASE SELECTING FROM SEPSIS, SEPTIC SHOCK, ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) OR MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS)
    Publication number: 20230190740
    Abstract: This invention relates to the new use of neurokinin-1(NK-1) receptor antagonists for treating sepsis, septic shock, systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS). The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists and combinations with one or more therapeutic agents, for such uses.
    Type: Application
    Filed: March 30, 2021
    Publication date: June 22, 2023
    Applicant: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE
    Publication number: 20230174552
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: January 13, 2023
    Publication date: June 8, 2023
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike TROWER, Monica LAZARO, Derek BUSH, David ELDER, Mary KERR
  • Method of treatment of symptoms of menopause
    Patent number: 11591346
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: February 28, 2023
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • NOVEL USES
    Publication number: 20210369707
    Abstract: This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 2, 2021
    Applicant: NeRRe Therapeutics Limited
    Inventors: Mike Trower, Stephen Pawsey, Mary Kerr
  • NOVEL USES
    Publication number: 20210236506
    Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
    Type: Application
    Filed: February 10, 2021
    Publication date: August 5, 2021
    Applicant: KaNDy Therapeutics Limited
    Inventor: Mike Trower
  • NOVEL USES
    Publication number: 20210128574
    Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
    Type: Application
    Filed: November 6, 2018
    Publication date: May 6, 2021
    Applicant: KaNDy Therapeutics Limited
    Inventor: Mike Trower
  • METHOD OF TREATING CERTAIN SEX HORMONE-DEPENDENT DISEASES ADMINISTERING A SOFT GELATIN CAPSULE COMPRISING NK1 AND NK3 RECEPTORS ANTAGONISTS
    Publication number: 20200361957
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: August 4, 2020
    Publication date: November 19, 2020
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE
    Publication number: 20200361956
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis (trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: August 4, 2020
    Publication date: November 19, 2020
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • Soft gelatin capsule formulation
    Patent number: 10774091
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 15, 2020
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • NOVEL PHARMACEUTICAL FORMULATION
    Publication number: 20190284205
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: March 13, 2019
    Publication date: September 19, 2019
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • Uses of dual NK1/NK3 receptor antagonists for treating sex-hormone diseases
    Patent number: 10195205
    Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: February 5, 2019
    Assignee: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
    Patent number: 9907795
    Abstract: This invention relates to the new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-?]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it and one or more therapeutic agents for the treatment of chronic cough, including chronic refractory cough and to combinations for such a use.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: March 6, 2018
    Assignee: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • NOVEL USES
    Publication number: 20170326140
    Abstract: This invention relates to a new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of Interstitial lung diseases (ILDs), including IPF, and to combinations for such uses.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 16, 2017
    Applicant: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • METHOD OF TREATMENT OF CHRONIC COUGH ADMINISTERING ORVEPITANT IN COMBINATION WITH OTHER THERAPEUTIC AGENTS
    Publication number: 20170326141
    Abstract: This invention relates to the new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it and one or more therapeutic agents for the treatment of chronic cough, including chronic refractory cough and to combinations for such a use.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 16, 2017
    Inventor: Mike Trower
  • Orvepitant for chronic cough therapy
    Patent number: 9750739
    Abstract: This invention relates to the new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of chronic cough, including chronic refractory cough and to combinations for such a use.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: September 5, 2017
    Assignee: NeRRe Therapeutics Limited
    Inventor: Mike Trower